精華製藥(002349.SZ)子公司通過藥品GMP檢查及孫公司取得GSP證書
格隆匯1月17日丨精華製藥(002349.SZ)公佈,江蘇省藥品監督管理局於2020年1月16日在網上發佈了《江蘇省GMP檢查結果公告》(2020年第七號),江蘇省藥品監督管理局按照《藥品管理法(2019年修訂)》及國家藥品監督局《關於貫徹實施
<中華人民共和國藥品管理法>
有關事項的公告》,對公司子公司江蘇金絲利藥業有限公司(“金絲利藥業”)現場檢查,金絲利藥業符合《藥品生產質量管理規範(2020年修訂)》要求,具體信息如下:
中華人民共和國藥品管理法>
企業名稱:江蘇金絲利藥業有限公司;檢查範圍:生物製品(注射用重組人白介素-2,凍乾粉針劑);檢查時間:2019.10.24-2019.10.27。
金絲利藥業控股子公司江蘇蘇欣醫藥有限公司(“蘇欣醫藥”)於近日收到江蘇省藥品監督管理局核發的《藥品經營質量管理規範認證證書》(“GSP”證書),該證書信息如下:
證書編號:A-JS20-003;企業名稱:江蘇蘇欣醫藥有限公司;地址:宜興環科園興業路1號;認證範圍:批發;有效期至:2025年1月7日。
公司持有金絲利藥業49.37%股份,金絲利藥業持有蘇欣醫藥51%股份,金絲利藥業GMP檢查通過和蘇欣醫藥取得GSP證書有利於提升公司競爭力,將對公司未來生產經營產生積極影響,
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.